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CREB-binding protein and p300 function as transcriptional coactivators in the regulation of gene expression through
various signal-transduction pathways. Both are potent histone acetyl transferases. A certain level of CREB-binding
protein is essential for normal development, since inactivation of one allele causes Rubinstein-Taybi syndrome
(RSTS). There is a direct link between loss of acetyl transferase activity and RSTS, which indicates that the disorder
is caused by aberrant chromatin regulation. We screened the entire CREB-binding protein gene (CBP) for mutations
in patients with RSTS by using methods that find point mutations and larger rearrangements. In 92 patients, we
were able to identify a total of 36 mutations in CBP. By using multiple ligation-dependent probe amplification, we
found not only several deletions but also the first reported intragenic duplication in a patient with RSTS. We
extended the search for mutations to the EP300 gene and showed that mutations in EP300 also cause this disorder.
These are the first mutations identified in EP300 for a congenital disorder.
Introduction
Rubinstein-Taybi syndrome (RSTS [MIM 180849]) is a
congenital disorder characterized by mental and growth
retardation and a wide range of typical dysmorphic
features. Facial dysmorphology includes down-slanted
palpebral fissures, a broad nasal bridge, a beaked nose,
and micrognathia. Particularly noticeable are the broad
thumbs and broad big toes. In addition, patients with
RSTS have an increased risk of tumor formation. Al-
though various types of tumors have been described,
there is an excess of tumors arising from developmental
defects and tumors in brain or neural-crest cell–derived
tissue (Miller and Rubinstein 1995). Mutations in the
gene encoding the CREB-binding protein (CREBBP, also
known as “CBP”), located on chromosome 16p13.3,
were found to be responsible for causing the disorder
(Petrij et al. 1995).
The protein, CBP, serves as a transcriptional coacti-
vator (Kwok et al. 1994). It has a transactivation do-
main but does not specifically bind to DNA. The name
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of the protein is based on the interaction with the CRE-
binding protein (CREB); however, CBP interacts with a
large number of other proteins as well. It is thought that
CBP acts as an integrator of the signals from various
pathways (Goodman and Smolik 2000). Transcription
factors downstream from these pathways need to com-
pete with each other for the limited amount of CBP
available in the nucleus. The protein forms a physical
bridge between the DNA-binding transcription factors
and the RNA polymerase II complex. In addition, CBP
has intrinsic histone acetyl transferase (HAT) activity
(Bannister and Kouzarides 1996). By acetylating his-
tones, CBP opens the chromatin structure at the locus
that needs to be expressed, a process essential for gene
expression. CBP is also capable of acetylating a large
number of other proteins—for example, the transcrip-
tion factor p53 (Gu and Roeder 1997).
Although RSTS is considered to be an autosomal
dominant disorder, patients with RSTS very rarely have
children. Almost all mutations, therefore, occur de
novo. The mutations found in patients vary from rel-
atively large microdeletions, which remove the entire
gene, to point mutations. In addition, five translocations
and two inversions disrupting the gene have been re-
ported (Petrij et al. 2000). The microdeletions that re-
move the entire gene indicate that haploinsufficiency is
the ultimate cause of the syndrome. Presumably, at crit-
ical moments during development, the amount of CBP
drops below a certain threshold because of the loss of
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one allele. How this loss of the allele actually causes
the particular symptoms of RSTS, however, is unclear.
Nevertheless, we know from studies of patients with
missense mutations and splice-site mutations that affect
only the HAT domain of CBP that a loss of HAT activity
is sufficient to cause the syndrome (Murata et al. 2001;
Kalkhoven et al. 2003).
To elucidate the complete spectrum of mutations, we
screened 92 patients with RSTS for point mutations,
small deletions or insertions, and large deletions and
duplications. Because we could not find mutations in
the CBP gene in the majority of our patients, we as-
sumed that the remaining patients have mutations in
other genes.
CBP shares homology with another protein, p300,
which is encoded by the EP300 gene on chromosome
22q13.2 (Lundblad et al. 1995). Both proteins are par-
ticularly homologous at their binding sites for tran-
scription factors, and p300 also has a HAT domain.
Like CBP, it serves as a transcriptional coactivator.
EP300 is therefore a likely gene candidate to screen,
and, indeed, we found three mutations in our analysis
of the gene. These are the first mutations found in
EP300 for a congenital disorder, and, in addition, they
prove that RSTS is a genetically heterogeneous disorder.
Material and Methods
The majority of DNA samples described in this study
were sent to us by clinicians in the Netherlands and
many other countries in the form of soluble genomic
DNA from patients with a clinical diagnosis of RSTS.
DNA from the remainder of the patients was isolated
from peripheral blood in our laboratory by use of stan-
dard protocols. The study was reviewed by the institu-
tional review board of the Leiden University Medical
Center. Parents or guardians of patients provided oral
or written consent for molecular studies. DNA from
92 patients was analyzed. The 92 patients included
some patients who have been presented in previous
publications: mutations affecting the HAT domain have
been described by Kalkhoven et al. (2003), and an
mRNA deletion in patient 127-2 was described by Petrij
et al. (2000), although no genomic mutation was found.
Sequence variants were checked using a set of 98 con-
trol chromosomes. When possible, DNA from the par-
ents of patients was analyzed to determine whether se-
quence variants occurred de novo.
Denaturing Gradient Gel Electrophoresis (DGGE)
DGGE was performed with a GC clamp on either the
forward or the reverse primer (see table A1 [online
only]). To screen the splice sites and branch sites, primers
were selected to anneal to the flanking intron sequences
and were chosen by use of either WINMELT (Biorad)
or MELT-INGENY (Ingeny B.V.) software. All oligo-
nucleotides were synthesized by Sigma-Aldrich. Am-
plified fragments were analyzed on 9% polyacrylamide
gels (acrylamide:bisacrylamide, 37.5:1), with various
linear denaturing gradients, optimized for each frag-
ment, on the DCode system from Biorad. Gels were run
at 90 V at a constant temperature of 60C. An acrylam-
ide mixture with 40% formamide and 7 M urea was
defined as 100% denaturant, and acrylamide without
these denaturing agents was defined as 0% denaturant.
SSCP Analysis
Electrophoresis was performed at room temperature
by use of two types of gels. The first type was a poly-
acrylamide gel (acrylamide:bisacrylamide, 49:1) with
1 # Tris borate EDTA (TBE) without glycerol, and the
second type was 0.5 # Mutation Detection Enhance-
ment (National Diagnostics) with 0.6# TBE and 10%
glycerol. During amplification, the fragments for SSCP
analysis were radioactively labeled, either by incorpo-
ration of a32P-dCTP or by use of primers that were phos-
phorylated using g32P-dATP (Amersham). Visualization
of the fragments was done using the PhosphorImager
(Molecular Dynamics).
Multiple Ligation-Dependent Probe Amplification
Probes were designed for 20 exons of the CBP and
EP300 genes. Multiple ligation-dependent probe ampli-
fication (MLPA) was performed as described by White
et al. (2004); however, for some samples, the amplifi-
cations with the multiplex amplifiable probe hybrid-
ization (MAPH) and MLPA primers were performed in
separate reactions. All samples in which rearrangements
were found were tested at least twice.
Sequencing and Restriction Digestions
Sequencing was performed on the ABI 3700 from Ap-
plied Biosystems by use of the manufacturer’s standard
protocol and reagents. Restriction digestions were per-
formed in accordance with the instructions of the man-
ufacturer. Digestions or second sequencing reactions to
confirm the first results were done on PCR fragments
generated in an independent reaction. The deletion of 8
nt in patient 256-1 was confirmed by PCR with an allele-
specific primer, TCCTCCATCTACTAGTAGTG, that
skips the deleted part and anneals with two nucleotides
after the deletion. The reverse primer has the sequence
GTCCTAACCAAATCAAACAG.
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Results
Point Mutations and Small Deletions or Insertions
in CBP
We screened the entire CBP gene for point mutations
and small deletions or insertions, primarily by using
DGGE, and screened target sequences that were not
suited for DGGE by using SSCP analysis. The complete
coding sequence and splice sites of the CBP gene required
a total of 49 fragments, of which 40 were screened using
DGGE, which covered ∼83% of the coding sequence.
Direct sequencing was used to identify the mutation after
aberrant bands were found on DGGE or SSCP gels. All
mutations were confirmed either by digestion with re-
striction enzymes, when a restriction-enzyme site was
altered, or by a second sequence analysis.
In 92 patients, we found a total of 27 mutations (table
1). The majority is predicted to lead to a premature
translation stop, but we also detected five putative mis-
sense mutations. Base substitutions leading to a pre-
mature stop codon, as well as deletions and insertions
leading to frame shifts, can be clearly identified as dis-
ease-causing mutations. On the other hand, a change of
amino acids is much less clear; however, patients with
RSTS, as a rule, have de novo mutations. Since we were
able to confirm three of the mutations as de novo, we
consider them the most likely to be disease causing. We
do not have parental DNA for patients 228-1 and 260-
1. All putative missense mutations are at the highly con-
served HAT domain of CBP, and the amino acids that
are changed have residues that are conserved in both the
mouse and the fruit fly (fig. 1).
Unless we have an RNA sample from a patient, we
cannot check whether a splice-site mutation actually
leads to aberrant splicing. These mutations, however,
should also comply with the rule that mutations in pa-
tients with RSTS occurred de novo. Except for the mu-
tation in patient 39-1, for which parental DNA was not
available, we could confirm the mutations in that way.
The GrA mutation in the splice-donor site flanking exon
24 in patient 39-1, however, is at the first position,
which—in all splice-donor sites, without exception—
should be a guanine. The splice-site mutation in patient
211-3 could be analyzed on RNA isolated from a cell
line. Subsequent sequence analysis proved that the mu-
tation in the splice-acceptor site flanking exon 22 leads
to a deletion of exon 22 in the processed mRNA (Kalk-
hoven et al. 2003)
Large Deletions and Duplications in CBP
Previous research suggests that ∼10% of the muta-
tions in patients with RSTS are microdeletions affecting
the CBP gene (Bartsch et al. 1999; Blough et al. 2000).
We performed a FISH analysis using five cosmids span-
ning the entire gene to detect such deletions, when meta-
phase chromosome spreads of patients were available
(Petrij et al. 2000). The recently developed technique of
MLPA can also be used to detect microdeletions in sol-
uble genomic DNA (Schouten et al. 2002). Because that
was the type of material available to us for the majority
of our patients, we performed MLPA to test the CBP
gene.
The resolution of MLPA is related to the number of
probes used. We made a set of 20 MLPA probe pairs,
covering most of the CBP gene. This allows us to screen
for deletions that cannot be detected by FISH. Southern
blotting could have been an alternative but is, in our
case, impractical—if not impossible—because it requires
so much DNA.
The quality of DNA is slightly more critical for MLPA
than for a normal PCR; therefore, we could not screen
all patients with MLPA who were screened with DGGE
and SSCP. In total, we screened 53 patients, and, for
controls, we used material from 3 patients with known
microdeletions that were detected using FISH, including
1 patient with a deletion of the entire CBP gene. Our
MLPA analysis detected those positive controls flaw-
lessly, and we found a number of previously undetected
mutations. We found a total of nine new deletions, which
ranged from single-exon deletions to the deletion of the
entire gene. One deletion, that of exon 2, has been de-
scribed elsewhere for the RNA level (Petrij et al. 2000).
At the time, Southern blots did not reveal a deletion in
the genomic DNA; therefore, it was not clear whether
this was a genomic deletion or a splicing aberration. This
mutation has been found in family 127, which consists
of an affected mother and child, one of the very few
cases of inherited RSTS.
In addition to the nine deletions, we also found a
duplication in one individual. Patient 162-1 has a du-
plication of the first exon of the CBP gene. How this
leads to the inactivation of this allele is not clear, but a
disease-causing duplication of the first exon has been
described in Opitz syndrome (Winter et al. 2003).
The exon 1 deletions and duplication were confirmed
using extra probe pairs—one probe at the promoter re-
gion and three probe pairs in intron 1 (see table A2
[online only]).
Mutations in EP300
Point-mutation detection and MLPA analysis of CBP
yielded a total of 36 mutations in 92 patients, strongly
suggesting that other genes could also be involved in
RSTS. The most likely candidate is the EP300 gene,
coding for p300, on chromosome 22q13.1. That gene
was screened using the same approach. We used 37
DGGE fragments, which covered ∼79% of the coding
sequence of EP300, and the remaining part was covered
Table 1
List of All Mutations Found in the CBP and EP300 Genes
Gene, Type of Mutation,
and Individual Exona Mutationa,b Protein Changec
CBP:
Nonsense mutation:
7-1 Exon 2 c.304 CrT Q102X
177-1 Exon 5 c.1237 CrT R413X
212-1d Exon 28 c.4669 CrT Q1558X
27-1 Exon 29 c.4879 ArT K1627X
2-1 Exon 31 c.6010 CrT R2004X
16-1 Exon 31 c.6133 CrT Q2045X
178-3 Exon 31 c.6283 CrT Q2095X
Missense mutation:
209-1d Exon 21 c.3823 GrAe E1278K
201-1 Exon 26 c.4340 CrTe T1447I
260-1 Exon 26 c.4348 TrC Y1450H
228-1 Exon 27 c.4409 ArG H1470R
2644d Exon 30 c.4991 GrAe R1664H
Deletion/insertion:
153-1 Exon 2 c.235 del G G79fsX86
199-3 Exon 3 c.904_905 del AGe S302fsX348
205-1 Exon 6 c.1381_1388 del 8e G461fsX469
239-1 Exon 6 c.1481 dup A N494fsX527
203-1 Exon 8 c.1735 dup Ae A581fsX586
57-3 Exon 18 c.3396_3400 del 6 P1132fsX1166
10-1 Exon 18 c.3432_3433 del AG T1144fsX1168
232-1 Exon 21 c.3824 dup T F1275fsX1282
231-1d Exon 25 c.4256_4258 del CT S1419fsX1419
34-3 Exon 27 c.4399 del Ge V1467fsX1467
213-1d Exon 29 c.4837 del Ge V1613fsX1634
Splice-site mutation:
198-3d Exon 20 c.3779 5 GrCe
211-3d Exon 22 c.3837 2 ArTe
47-3 Exon 23 c.3915 1 GrAe
39-1d Exon 24 c.4133 1 GrA
Rearrangementf:
267-1 Del exon 1 c.-198-?_85? del
36-3 Del exon 1_2 c.-198-?_798? del
74-1 Del exon 1_19 c.-198-?_3698? del
15-1 Del exon 1_31 c.-198-?_1150? del
41-3 Del exon 1_31 c.-198-?_1150? del
127-2g Del exon 2 c.86-?_798? del
252-1 Del exon 12 c.2159-?_2283? del
253-1 Del exon 31 c.5173-?_1150? del
162-1 Dup exon 1 c.-198-?_85? dup
EP300:
254-1 Exon 10 c.1942 CrTe R648X
256-1 Exon 15 c.2877_2884 del 8e S959fsX966
149-1 Del exon 1 c.-1200-?_94? dele
a Del p deletion; dup p duplication.
b The mutations are denoted in accordance with the nomenclature published by den
Dunnen and Antonarakis (2001). A question mark (?) indicates that the breakpoint is
unknown. The changes on the DNA level have been confirmed by restriction digests or by
second sequencing reactions. CBP mutations are described in relation to GenBank sequence
NM_004380, and EP300 mutations are described in relation to GenBank sequence
NM_001429.1, with the A of the ATG start codon counted as nucleotide 1.
c The changes on the protein level are predictions.
d The mutations in these patients have been published previously by Kalkhoven et al.
(2003)
e De novo mutation.
f Rearrangements found by MLPA.
g The mutation found in this patient has been described as an mRNA deletion by Petrij
et al. (2000), but the genomic lesion was not found.
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Figure 1 Conservation of amino acids that are predicted to
change by missense mutations. All five mutations we found that are
predicted to change the amino acid residues are situated in the high-
ly conserved HAT domain. The changed residues are conserved in
man (Homo sapiens [Hs]), mouse (Mus musculus [Mm]), and the fruit
fly (Drosophila melanogaster [Dm]). Numbers indicate individual
patients.
by 10 SSCP fragments. MLPA was performed using a
set of 20 exon-specific probe pairs.
Indeed, three inactivating mutations were detected in
the EP300 gene (fig. 2). Two mutations were found using
DGGE. One mutation, in exon 10, is a transition (c.1942
CrT) that converts the triplet coding for an arginine at
position 648 into a stop codon. The other mutation, in
exon 15, is a deletion of 8 nt that predicts a frameshift
from codon 959, with a stop codon after 7 aa. The exact
location of the 8-bp deletion (c.2877_2884) was con-
firmed with allele-specific PCR. We analyzed DNA from
the healthy parents of both patients by use of DGGE
and sequencing and confirmed that the mutations oc-
curred de novo. The biological parentage was confirmed
by genotyping with 17 independent markers (data not
shown). Both mutations lead to predicted proteins less
than half their normal size that do not contain the HAT
domain. The third mutation, a deletion of the first exon,
was found using MLPA. Four probes revealed this de-
letion—two probes upstream of exon 1, one in exon 1,
and the fourth in intron 1—to be close to the first exon.
They all showed a decreased signal, whereas a probe in
exon 2 showed a normal dosage (fig. 2C). It is probable
that this deletion will lead to no expression from the
affected allele.
Discussion
We undertook a rigorous screening for point mutations,
small deletions or insertions, and large deletions and
duplications at the coding section of CBP by using ge-
nomic DNA from a large set of patients with RSTS.
There is neither a predominant type of mutation nor a
clear indication of a clustering of mutations within the
CBP gene. If we take a look at missense mutations, how-
ever, we see that they are all situated in the HAT domain
of CBP. We have published some of these mutations else-
where and have shown that they affect the HAT activity
of CBP (Kalkhoven et al. 2003). In addition, two articles
each reported a de novo missense mutation in the HAT
domain, clearly underpinning the importance of this do-
main in relation to the disorder (Murata et al. 2001;
Bartsch et al. 2002). In contrast to our findings, a study
by Coupry et al. (2002) reported four putative missense
mutations of which only one was situated in the HAT
domain. The sequence variations were not found in the
other patients, and the affected residues were conserved
in mouse and were therefore considered to be causative
for RSTS. Whether these mutations actually arose de
novo could not be confirmed.
We have found mutations in less than half of the
patients (∼40%), which is comparable to the outcome
of the study by Coupry et al. (2002). DGGE and SSCP
analyses, together with detection of nucleotide substi-
tutions, are capable of identifying only relatively small
deletions and insertions. To detect larger deletions, we
chose to perform MLPA for CBP and EP300. We now
have shown that MLPA is capable of detecting deletions
in the CBP gene that were previously identified by FISH.
Because we have probe pairs corresponding to the ma-
jority of exons in both CBP and EP300, our MLPA
screening also negates the need for Southern blotting.
The use of MLPA has increased the power to detect
mutations, enabling us to find smaller deletions than
could be detected using FISH.
Nevertheless, the combined analysis of our samples
with both MLPA and DGGE or SSCP analysis found
mutations in less than half of the patients. It is probable
that some of the patients we screened will be regarded,
upon closer clinical examination, as having a different
syndrome that resembles RSTS; however, we think the
majority of these patients may be considered as having
true RSTS. Diagnosis of the syndrome has been per-
formed by many clinicians, but we did not find that
some have a significantly better record, in terms of the
number of mutations found, than others. In addition,
the set of patients with RSTS who were screened by
Coupry et al. (2002) had been carefully ascertained, yet
mutations were not found in more than half their pa-
tients as well. Either the CBP gene is mutated at parts
that we did not screen, such as the promoter or other
regulatory elements, or the mutations are in other genes.
The unscreened parts of the CBP gene may harbor some
mutations, but it is highly unlikely that they contain the
majority of RSTS-related mutations that have not yet
been identified in these patients. Indeed, RSTS is ge-
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Figure 2 Mutations in EP300 in patients with RSTS. A, Results
for patient 254-1. DGGE analysis of patient 254-1 and the healthy
parents shows that only the affected child has the mutation. Subsequent
sequence analysis revealed a transition, c.1942 CrT, that predicts the
protein change p.Arg648X in this patient. B, Results for patient 256-
1. DGGE analysis of family 256 shows a de novo mutation. The allele-
specific PCR confirms the exact location of the deletion seen by se-
quence analysis. The patient has an 8-bp deletion (c.2877_2884 del)
with the following sequence (deleted region is in capital letters; nu-
cleotides of allele-specific forward primer are underlined): gcctcctccatc-
tactagtagCACAGAAGtgaat. The forward primer skips the deleted part
and anneals with two nucleotides after the deletion. Only DNA from
the patient shows a band of 168 bp, whereas, in the lanes for DNA
from the healthy parents, only the prominently visible primer dimers
can be seen. C, Bar diagram of MLPA results for patient 149-1. MLPA
reveals a deletion at the first exon of EP300. The X-axis shows the
DNA probes. The probes upstream of the first exon are at positions
787–716 and 5–54 bp before the transcription start site (indicated by
787 and 54, respectively). Ex p exon; Int p intron. The Y-axis
represents the dosage of DNA: a dosage of 1 indicates the presence
of the normal amount of DNA—that is, both alleles are present—
whereas a dosage of ∼0.5 typically indicates a deletion of one allele.
The diagram clearly shows that the deletion runs from the upstream
region of exon 1 into intron 1 and that exons 2 and 3 are present for
both alleles. The exact size of the deletion is unknown.
netically heterogeneous, since we identified mutations
in the EP300 gene.
The finding of the EP300 mutations raises the ques-
tion of whether there are phenotypic differences asso-
ciated with EP300 mutations as compared with CBP
mutations (fig. 3). The phenotypes of the patients were,
in most respects, compatible with classic RSTS: all pa-
tients had heavy and arched eyebrows, long eye lashes,
a prominent nose with a long hanging columella, and
a pouting lower lip. One patient had a small chin. It is
interesting that only one patient showed a very mild
downward-slanting of the palpebral fissures, and none
had the grimacing smile. As mentioned above, all had
a shortened and broad thumb and square distal finger-
tips, and two had visible fetal pads. Also, the big toe
was broad in all patients. One patient had a remarkably
short first metatarsal bones, giving rise to a very prox-
imal placement of the halluces. Similar dysmorphology
has been found in a patient who also has a deleted CBP
gene (Petrij et al. 1995). In all three patients with EP300
mutations, the forefoot was broad and the fifth toe was
shorter than normal. The small number of patients pre-
vents any of these findings from being firm conclusions.
Strikingly, the number of identified patients with
RSTS who have EP300 mutations, currently three, is
small compared with the number of identified patients
with RSTS and CBP mutations (36 patients). Possibly,
this ratio of 1:12 represents the different chances of
mutations occurring in these two genes. Alternatively,
the EP300 gene could have a mutation rate equal to
that of the CBP gene, with the majority of mutation
carriers not yet diagnosed as having RSTS. In view of
this latter explanation, it is interesting that we found
many more polymorphisms in the EP300 gene, includ-
ing some that lead to amino acid changes (data not
shown). Nevertheless, the majority of point mutations
found in the CBP gene are likely to lead to truncated
proteins, and two mutations in the EP300 gene are also
predicted to truncate the protein, so it is unlikely that
the mutation ratio can be entirely explain by differences
in the genotype-phenotype relationship. Therefore, we
think that the mutation rates of the loci are different.
The CBP gene harbors an instable region around
exon 2. This region was designated as instable because
all translocation and inversion breakpoints could be
found in all patients with RSTS, except one—as could
all leukemia breakpoints for which CBP functions as a
fusion partner. In addition, this same genomic piece of
DNA proved very hard to clone at the time of positional
cloning of the RSTS gene (Giles et al. 1997). The de-
letion of exon 2 and the deletions and duplication of
exon 1 may be caused by this instable region. The in-
stability in this region, however, cannot explain the ma-
jority of deletions found at the CBP locus, since most
Figure 3 Photographs of the three patients with EP300 mutations. A, The face, a hand, and a foot of patient 149-1. B, A hand, a close-
up of the fingers with fetal pads, and a foot of patient 254-1. C, A hand, a foot, and an X-ray of the foot of patient 256-1. Patient 256-1 has
the overall typical appearance of a patient with RSTS, with the exception of the feet. The feet have abnormally short first metatarsal bones,
as can be clearly seen in the X-ray photograph. Although this is not a typical feature, it does appear in some other patients with RSTS, as well
as in individuals with mutations in CBP.
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of these deletions have their breakpoints elsewhere (Pe-
trij et al. 2000).
Although CBP and p300 have been shown to have
overlapping functions, there are subtle but clear differ-
ences between the two proteins (Kalkhoven 2004). Dur-
ing embryogenesis, CBP and EP300 have similar but
not completely overlapping expression patterns (Par-
tanen et al. 1999). In addition, experiments with F9
teratocarcinoma cell lines showed that retinoic acid sig-
naling is p300 dependent and does not require CBP,
whereas cAMP signaling depends on CBP and not p300
(Kawasaki et al. 1998; Ugai et al. 1999). Recent work
with transgenic mice indicated the importance of the
acetyl transferase function of p300 in myogenesis, but
the acetyl transferase function of Cbp does not seem
to be necessary for this process (Roth et al. 2003).
The skeletal abnormalities found in heterozygous Cbp
knockout mice have not been reported for heterozygous
Ep300 knockout mice (Tanaka et al. 1997). We, how-
ever, do not find very striking phenotypical differences
between patients with mutations in the EP300 gene ver-
sus the CBP gene.
Double-heterozygous knockout mice for the Cbp and
Ep300 genes resemble the homozygous knockout mice
for either gene, in that all three types of mice die in
utero, a finding which led to the idea that the combined
levels of CBP and p300 are critical during development
(Yao et al. 1998). Our findings support this hypothe-
sis and reveal that even a relatively small decrease of
either protein has significant developmental conse-
quences. However, it is unclear how a decrease of either
protein leads to the specific features of RSTS. Perhaps
the partial loss of p300 is compensated for by recruit-
ment of CBP, and subsequent depletion of CBP then
leads to RSTS. Alternatively, both proteins could be
involved in a common function, and, therefore, the total
dosage would be required to prevent a syndrome like
RSTS. If so, then this common function has a relation-
ship with the HAT activity of the proteins because loss
of only the HAT activity of CBP causes RSTS (Murata
et al. 2001; Kalkhoven et al. 2003).
Interestingly, there is a direct link between HAT ac-
tivity and long-term memory. Heterozygous Cbp knock-
out mice have diminished mental capabilities. Experi-
ments on these knockout mice revealed that inhibiting
histone deacetyltransferase could ameliorate the prob-
lems with long-term memory seen in the mice (Alarcon
et al. 2004). Transgenic mice with a dominant negative
Cbp gene, in which only the HAT activity was ablated,
also showed problems with long-term memory. Again,
this could be reversed by a histone deacetylase inhibitor
(Korzus et al. 2004). In view of these data, it is possible
that other proteins with HAT activity—or with a func-
tion coupled to HAT activity—may also be involved in
RSTS. After all, the three mutations we have found in
the EP300 gene, together with the CBP gene mutations,
still leave us with more than half of the cases of RSTS
unaccounted for.
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